Clinical Intelligence

Verinata Health releases top-line results for Verifi prenatal test

Monday, February 13, 2012 03:41 PM

Verinata Health, a privately-held company dedicated to maternal and fetal health, has released top-line results from its prospective, blinded, multicenter validation study to detect fetal chromosomal aneuploidies, or an abnormal number of chromosomes, across the entire genome.

More... »

OncoSec doses first patients in phase II Merkel cell carcinoma study

Monday, February 13, 2012 03:22 PM

OncoSec Medical has treated several patients in an open-label, phase II clinical trial evaluating OncoSec's OMS (OncoSec Medical System) ElectroImmunotherapy for the treatment of Merkel cell carcinoma (MCC).

More... »

Valley Hospital to begin phase II trial of personalized vaccine for brain tumors

Friday, February 10, 2012 03:43 PM

Valley Hospital in Ridgewood, N.J., is now offering patients with newly diagnosed glioblastoma multiforme (GBM) (brain tumor) the opportunity to take part in a clinical trial that produces and uses a vaccine produced from patients' own tissue.

More... »

Lorediplon has best-in-class results for insomnia

Friday, February 10, 2012 03:38 PM

Ferrer, a privately-held Spanish pharmaceutical company, has released results from a phase I trial of Lorediplon in insomnia showing it has a best-in-class efficacy profile in terms of sleep maintenance and sleep quality when compared to market leader zolpidem.

More... »

Vyvanse capsules approved to treat adults with ADHD

Friday, February 10, 2012 12:08 PM

The FDA has approved Vyvanse (lisdexamfetamine dimesylate) capsules as a maintenance treatment for adults with ADHD, according to Shire Pharmaceuticals, a global specialty biopharmaceutical company.

More... »

FDA clears IND for treatment of acute seizures

Friday, February 10, 2012 12:06 PM

The FDA has cleared Neurelis’ Investigational New Drug application (IND) to commence clinical trials advancing the development of NRL-1, a diazepam nasal spray for the treatment of acute breakthrough seizures, according to Neurelis.

More... »

GW receives Austrian approval for cannabis-based oral spray for MS

Friday, February 10, 2012 12:04 PM

GW Pharmaceuticals’ Sativex (THC and cannabidiol) oral spray has received regulatory approval in Austria as a treatment of spasticity due to Multiple Sclerosis (MS).

More... »

FDA approves Sklice lotion for head lice

Friday, February 10, 2012 12:01 PM

The FDA has approved Sklice (ivermectin) lotion 0.5% for the topical treatment of head lice in patients 6 months of age and older, according to Sanofi.

More... »

Myelin Repair and ENDECE Neural to develop MS treatment

Friday, February 10, 2012 11:58 AM

The Myelin Repair Foundation (MRF), a nonprofit research organization, and ENDECE Neural have formed a partnership to expedite the advancement of myelin regeneration drug candidates for Multiple Sclerosis (MS) patients through pre-clinical studies and into phase I trials.

More... »

Positive phase III results with investigational antipsychotic Cariprazine

Friday, February 10, 2012 11:52 AM

Forest Laboratories and Gedeon Richter have released preliminary top-line results from a phase III clinical trial of cariprazine (RGH-188), an investigational antipsychotic agent, in patients with acute mania associated with bipolar I disorder.

More... »